UCB makes a rare acquisition
The Belgian group has bolstered its epilepsy offering with a $1.9bn move on Zogenix.
Fortunes diverge for solo drug launchers
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
Ovid joins the rare epilepsy race
Ovid Therapeutics gets a mid-stage win in Dravet syndrome, but might have a hard time going up against Zogenix’s Fintepla.
Go or no go? A busy month ahead for US FDA decisions
June will be hectic for the US regulator, with many approval decisions due, including one for subcutaneous Arzerra in multiple sclerosis and Tazverik in follicular…